Hematologic disorder
MONDO:0005570A disease involving the hematopoietic system.
Also known as: blood disease, blood disorder, disease of hematopoietic system, disease of the blood and blood-forming organs, disease or disorder of haematopoietic system, disease or disorder of hematopoietic system, disorder of haematopoietic system, disorder of hematopoietic system
8503 clinical trials for this condition and its sub-types, 174 tagged with Hematologic disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hematologic disorder
-
Hematopoietic and lymphoid system neoplasm 692 trials · 6,319 incl. sub-types
9 sub-types
- Hematopoietic and lymphoid cell neoplasm 484 trials · 5,928 incl. sub-types Sub-types →
- Lymphoid hemopathy 0 trials · 4,275 incl. sub-types Sub-types →
- Myeloid hemopathy 0 trials · 1,762 incl. sub-types Sub-types →
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Lymph node neoplasm 5 trials · 59 incl. sub-types Sub-types →
- STAT3-related early-onset multisystem autoimmune disease 2 trials
- Cavernous hemangioma 1 trial Sub-types →
-
Leukocyte disorder 6 trials · 3,572 incl. sub-types
23 sub-types
- B-cell neoplasm 304 trials · 3,167 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,761 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Anemia 258 trials · 975 incl. sub-types
19 sub-types
- Aplastic anemia 110 trials · 411 incl. sub-types Sub-types →
- Normocytic anemia 0 trials · 180 incl. sub-types Sub-types →
- Microcytic anemia 0 trials · 130 incl. sub-types Sub-types →
- Hypochromic anemia 0 trials · 123 incl. sub-types Sub-types →
- Beta-thalassemia and related diseases 0 trials · 99 incl. sub-types Sub-types →
- Congenital anemia 0 trials · 58 incl. sub-types Sub-types →
- Anemia due to chronic disorder 34 trials
- Pure red-cell aplasia 5 trials · 24 incl. sub-types Sub-types →
- Neonatal anemia 7 trials · 23 incl. sub-types Sub-types →
- Deficiency anemia 3 trials · 16 incl. sub-types Sub-types →
- Pancytopenia 15 trials
- Anemia due to enzyme disorder 1 trial · 14 incl. sub-types Sub-types →
- Sideroblastic anemia 0 trials · 14 incl. sub-types Sub-types →
- Macrocytic anemia 0 trials · 11 incl. sub-types Sub-types →
- Hemoglobin C disease 2 trials
- Hereditary methemoglobinemia 0 trials · 1 incl. sub-types Sub-types →
- Hemoglobin D disease 0 trials
- Hemoglobin E disease 0 trials
- Hemoglobinopathy Toms River 0 trials
-
Erythrocyte disorder 7 trials · 616 incl. sub-types
2 sub-types
- Hemoglobinopathy 34 trials · 445 incl. sub-types Sub-types →
- Malaria 134 trials · 169 incl. sub-types Sub-types →
-
Blood coagulation disease 54 trials · 539 incl. sub-types
8 sub-types
- Inherited blood coagulation disorder 8 trials · 321 incl. sub-types Sub-types →
- Coagulation protein disease 13 trials · 272 incl. sub-types Sub-types →
- Thrombotic microangiopathy 26 trials · 151 incl. sub-types Sub-types →
- Thrombophilia 12 trials · 75 incl. sub-types Sub-types →
- Hemolytic-uremic syndrome 7 trials · 24 incl. sub-types Sub-types →
- Hemorrhagic disease of newborn 1 trial
- Marantic endocarditis 0 trials
- Prekallikrein deficiency 0 trials Sub-types →
-
Hemorrhagic disease 108 trials · 508 incl. sub-types
28 sub-types
- Hemophilia A 178 trials Sub-types →
- Purpura 4 trials · 117 incl. sub-types Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Vascular hemostatic disease 62 trials · 63 incl. sub-types Sub-types →
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Inherited bleeding disorder, platelet-type 6 trials · 26 incl. sub-types Sub-types →
- Acquired hemophilia 2 trials · 7 incl. sub-types Sub-types →
- Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types Sub-types →
- Factor VII deficiency 6 trials Sub-types →
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Fetal and neonatal alloimmune thrombocytopenia 4 trials Sub-types →
- Acquired von willebrand syndrome 3 trials
- Factor X deficiency 2 trials Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- East Texas bleeding disorder 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Combined deficiency of factor V and factor VIII 0 trials Sub-types →
- Congenital factor V deficiency 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Hemophilia B leyden 0 trials
- Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation 0 trials
- Inherited prekallikrein deficiency 0 trials
- Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome 0 trials
- Prothrombin deficiency 0 trials Sub-types →
- Thrombomodulin-related bleeding disorder 0 trials
-
Blood platelet disease 18 trials · 369 incl. sub-types
5 sub-types
- Thrombocytopenia 74 trials · 266 incl. sub-types Sub-types →
- Thrombocytosis disease 7 trials · 71 incl. sub-types Sub-types →
- Inherited bleeding disorder, platelet-type 6 trials · 26 incl. sub-types Sub-types →
- Qualitative platelet defect 6 trials
- TPM4-related platelet disorder 0 trials
-
Splenic disorder 3 trials · 248 incl. sub-types
8 sub-types
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Hypersplenism 12 trials
- Splenic sequestration 1 trial
- Congestive splenomegaly 0 trials Sub-types →
- Splenic abscess 0 trials
- Splenic infarction 0 trials
- Splenic tuberculosis 0 trials
- Wandering spleen 0 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Congenital hematological disorder 1 trial · 101 incl. sub-types
21 sub-types
- Congenital anemia 0 trials · 58 incl. sub-types Sub-types →
- Constitutional neutropenia 2 trials · 28 incl. sub-types Sub-types →
- Congenital thrombotic thrombocytopenic purpura 5 trials
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- GNE myopathy 3 trials
- Congenital amegakaryocytic thrombocytopenia 1 3 trials
- Leukocyte adhesion deficiency type II 2 trials
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Thrombocytopenia-absent radius syndrome 1 trial
- Congenital agammaglobulinemia 0 trials Sub-types →
- Congenital analbuminemia 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
- Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome 0 trials
- Congenital secondary polycythemia 0 trials Sub-types →
- Hereditary thrombocytosis with transverse limb defect 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptodactyly syndrome 0 trials
- Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome 0 trials Sub-types →
- Sulfhemoglobinemia, congenital 0 trials
-
Monoclonal gammopathy 24 trials · 68 incl. sub-types
3 sub-types
-
Premalignant hematological system disease 3 trials · 25 incl. sub-types
2 sub-types
- Clonal hematopoiesis 10 trials · 22 incl. sub-types Sub-types →
- Atypical lymphoproliferative disorder 0 trials
-
Paraneoplastic hematological syndrome 0 trials · 9 incl. sub-types
2 sub-types
- POEMS syndrome 8 trials
- Humoral hypercalcemia of malignancy 1 trial
-
Parasitemia 5 trials
-
Blood group incompatibility 2 trials
1 sub-type
- Rh isoimmunization 0 trials
-
L-ferritin deficiency 1 trial
-
Hyperamylasemia 1 trial
-
Bloom syndrome 0 trials
-
GATA1-Related X-Linked Cytopenia 0 trials
-
Polyclonal hyperviscosity syndrome 0 trials
-
Septicemic plague 0 trials
Most studied deeper sub-types
-
Gene editing offers hope for a One-Time sickle cell cure
Cure CompletedResearchers are testing a one-time gene therapy called exa-cel for people with severe sickle cell disease. The treatment uses CRISPR-Cas9 to edit a patient's own blood stem cells, which are then infused back after chemotherapy. The trial measures whether participants remain free …
Phase 2/3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
One-shot gene therapy aims to free hemophilia patients from constant infusions
Disease control CompletedThis trial tests a gene therapy called valoctocogene roxaparvovec for people with severe hemophilia A who have developed inhibitors (antibodies that block standard treatment). The therapy uses a harmless virus to deliver a working copy of the gene for clotting factor VIII, so the…
Phase 1/2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug cuts chemotherapy side effect by over 60% in breast cancer patients
Disease control CompletedThis study tested whether Naderin, an immune-boosting drug, could prevent low white blood cell counts in 79 women with breast cancer receiving first-line chemotherapy. Participants either received Naderin alongside chemotherapy or chemotherapy alone. The results showed that only …
Phase 2/3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase 1/2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
CAR T-Cell therapy shows promise for Hard-to-Treat multiple myeloma
Disease control CompletedThis study tested a treatment called anti-BCMA CAR T-cell therapy in 40 adults with multiple myeloma whose disease did not respond well enough to a stem cell transplant and maintenance therapy. The goal was to see if this one-time cell therapy could help more patients achieve a c…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo pill shows promise for stubborn leukemia
Disease control CompletedThis phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to ad…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Blood cancer drug safety checked in small Follow-Up study
Disease control CompletedThis study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo aims to tame deadly transplant complication
Disease control CompletedThis phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Acid lock could fight blood infections in cancer patients
Disease control CompletedThis study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New dosing study aims to tame Drug-Resistant leukemia
Disease control CompletedThis study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New Immune-Blocking drug tested in humans for first time
Disease control CompletedThis early-stage study tested RLYB116, a small protein that blocks a part of the immune system called complement, in 16 healthy adults. The main goal was to see if it is safe and how the body handles it. Researchers also checked how well it stops complement activity. This is a fi…
Phase 1 • Sponsor: Rallybio • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Laser surgery or watchful waiting? trial seeks best care for twin syndrome
Disease control CompletedThis trial compared two approaches for twin-to-twin transfusion syndrome (TTTS) stage 1: immediate laser surgery versus careful observation. 179 pregnant women with TTTS stage 1 and favorable conditions took part. The goal was to see which strategy leads to better survival and br…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental CAR-T therapy targets tough blood cancers in tiny early trial
Disease control CompletedThis early-phase study tested a new cell therapy called RD13-02 in just 2 people with relapsed or refractory CD7-positive blood cancers (like T-cell leukemia or lymphoma). The treatment uses specially engineered immune cells to attack cancer cells. The main goals were to check sa…
Early phase 1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New melphalan combo shows promise in Half-Matched transplants for blood cancer patients
Disease control CompletedThis study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approac…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug shows promise for Hard-to-Treat blood cancer
Disease control CompletedThis study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill could cut blood transfusions for blood disorders
Disease control CompletedThis Phase 2 study tested an experimental drug called etavopivat in 53 people with thalassemia or sickle cell disease. The goal was to see if the pill could safely reduce the number of red blood cell transfusions needed and raise hemoglobin levels. Participants took 400 mg of eta…
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
CRISPR gene editing offers hope for thalassemia patients to ditch transfusions
Disease control CompletedThis study tested a single treatment using CRISPR gene editing to modify a person's own blood stem cells, aiming to help people with severe beta-thalassemia stop needing regular blood transfusions. 59 participants received the therapy and were monitored for safety and how long th…
Phase 2/3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug aims to cut sickle cell pain episodes
Disease control CompletedThis study tested a drug called inclacumab in about 240 people with sickle cell disease who experience painful vaso-occlusive crises. Participants received either inclacumab or a placebo by IV infusion. The main goal was to see if inclacumab could reduce the number of these painf…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
One-Time gene therapy shows promise for hemophilia a
Disease control CompletedThis study tested a one-time gene therapy (valoctocogene roxaparvovec) in 22 adults with severe hemophilia A. The treatment aims to help the body produce its own clotting factor VIII, reducing the need for regular infusions. Participants also received steroids to manage immune re…
Phase 3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Real-World study tracks Alprolix's bleeding control in hemophilia b
Disease control CompletedThis study followed 151 people with hemophilia B who were already using or starting Alprolix, a long-lasting clotting factor. Over 24 months, researchers tracked how often bleeding occurred, how often the drug was injected, and how much was used. The goal was to see how well Alpr…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Targeted drug shows promise for rare blood cancer in completed trial
Disease control CompletedThis completed Phase 4 trial tested the drug brentuximab vedotin in 50 adults with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL), a rare blood cancer. Participants had already received at least one round of chemotherapy. The study measured how many patien…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 19:04 UTC
-
New blood test could speed up infection diagnosis
Diagnosis CompletedThis study tested a new diagnostic device, the QIAstat-Dx panels, to see how well it identifies bacteria in blood samples from people with suspected bloodstream infections. Researchers compared the test results to standard methods using over 2000 samples. The goal is to provide f…
Sponsor: QIAGEN Gaithersburg, Inc • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Can Blood-Type-Matched platelets make transfusions safer?
Symptom relief CompletedResearchers are testing a new way to prepare platelets for transfusion that matches a patient's ABO blood type. The study enrolls adults aged 18 to 65 who need platelet transfusions for blood disorders. Doctors measure platelet counts and bleeding before and after transfusion to …
Phase 4 • Sponsor: The General Hospital of Western Theater Command • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Could carbon monoxide be a medicine? new trial for sickle cell
Symptom relief CompletedThis study tests a new liquid drug called HBI-002, which contains carbon monoxide, in 9 people with sickle cell disease aged 14 to 55. Participants take the drug daily for 14 days to see if it is safe and helps with symptoms. The goal is to find a better way to manage this painfu…
Phase 2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
App aims to ease burden for stem cell transplant caregivers
Symptom relief CompletedThis study tested whether a mobile app called Roadmap 2.0 could improve the quality of life for caregivers and patients undergoing stem cell transplants. Over 370 caregivers and patients used a Fitbit tracker and answered surveys. Some also got the app with extra positive activit…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Sexual health help for stem cell survivors shows promise
Symptom relief CompletedThis study tested a program to help stem cell transplant survivors who have sexual problems. Participants met with a nurse for three months and got educational materials. The goal was to see if this improved their sexual satisfaction, quality of life, and mood. The study involved…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Monthly chat group may ease isolation for young transplant patients
Symptom relief CompletedThis study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Asthma drug may ease cancer treatment side effects
Symptom relief CompletedThis study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Heart rate training boosts exercise benefits for cancer survivors
Symptom relief CompletedThis study looked at whether adding heart rate biofeedback training to regular physical activity can improve quality of life for people who have finished treatment for blood cancers. 80 adults in remission took part. The goal was to see if this combination helps them feel better …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
VR rollercoasters vs. beach meditations: which changes your blood more?
Knowledge-focused CompletedThis study looked at how watching relaxing or stressful virtual reality (VR) content changes stress-related substances in the blood of 30 healthy adults. Participants watched a beach meditation or a rollercoaster ride for about 5 minutes, and blood was taken before and after. The…
Sponsor: Van Creveldkliniek • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Teens with blood disorders share their stories in new study
Knowledge-focused CompletedThis study interviewed 15 children aged 12 to 21 who have bleeding or clotting disorders. Researchers asked about their quality of life, confidence in managing their condition, and how they view the care they receive. The goal is to better understand the real-life challenges thes…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Steroids before birth may alter Baby's blood counts
Knowledge-focused CompletedThis study looked at whether steroids given to pregnant women before a premature delivery change the baby's blood counts. Researchers observed over 1000 premature infants and compared their blood results based on when and how much steroid the mother received. The goal was to unde…
Sponsor: Princess Anna Mazowiecka Hospital, Warsaw, Poland • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
AI and MRI join forces to speed up cancer radiation planning
Knowledge-focused CompletedThis completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Massive study reveals hidden struggles of stem cell survivors
Knowledge-focused CompletedThis study looked at over 1,200 people in Denmark who had a stem cell transplant for blood diseases, some as far back as 1970. Researchers used detailed surveys to measure late effects and quality of life. The goal is to find out what medical and personal factors help survivors f…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Lung scans reveal hidden patterns in blood disease patients
Knowledge-focused CompletedThis completed study examined lung CT scans from 148 adults with blood diseases to identify common patterns of lung involvement. Researchers tracked how often certain radiological features appeared and counted complications. The goal was to better understand the range of lung iss…
Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood clues: simple tests may forecast myeloma survival
Knowledge-focused CompletedThis study examined whether three blood measurements—blood thickness (viscosity), the balance of two proteins (albumin/fibrinogen ratio), and red blood cell size variation (RDW)—can help predict how newly diagnosed multiple myeloma patients will fare over the next year. Researche…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC